OncoSec rises on positive meeting with US FDA for cancer therapy

OncoSec Medical Incorporated

16/05/2023 17:44

** Shares of cancer drug developer OncoSec Medical Inc
 ONCS.O  rise 18.6% to $0.97 
    ** Co says it met with the U.S. Food and Drug Administration
to discuss a mid-stage study design to test its experimental
combination therapy to treat a type of skin cancer that can be
surgically removed   
    ** Co's experimental therapy in combination with Merck & Co
Inc's  MRK.N  Keytruda will be tested as a neoadjuvant
immunotherapy
    ** Neoadjuvant immunotherapy is given as a first step to
shrink a tumor before surgery
    ** The combination therapy had earlier failed to meet the
main goal in a mid-stage study testing it for advanced
unresectable skin cancer 
    ** Including session gains, stock down ~43% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))